Trial Profile

A Phase II trial of NNZ-2591 for Phelan-McDermid syndrome

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NNZ 2591 (Primary)
Indications Telomeric 22q13 Monosomy Syndrome
Focus Therapeutic Use
Sponsors Neuren Pharmaceuticals

Most Recent Events

01 Jun 2021 According to a Neuren Pharmaceuticals media release, company received clear and constructive guidance from pre-IND meetings with the FDA Office of Neuroscience. Company expect to commence this trial as planned in H2 2021, aiming for top-line results in H2 2022.
11 Jan 2021 According to an Neuren Pharmaceuticals media release, the company plans to initiate this study in 2021.
06 Mar 2020 According to an Neuren Pharmaceuticals media release, the company plans to test treatment with NNZ-2591 for 12 weeks in the Phase 2 trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com